News

REVIVE-1 is a 600-patient double-blinded, global, multicenter trial, in patients with ABSSSI that compares the safety and efficacy of an 80mg intravenous dose of iclaprim with 15mg/kg intravenous

The project builds on work at the university to understand the role apelin receptors play in cardiovascular diseases. The collaboration gives Heptares access to a group run by Anthony Davenport,

The drug is approved as the first adjunctive therapy in the European Union (EU) for patients aged two years and older. The EC’s decision marks the third TSC-related

The Appeals Court ruling affirmed the September 30, 2015 decision reached by the United States District Court for the Northern District of Illinois upholding Cumberland's patent and expressly

EyeGate OBG is being developed to accelerate re-epithelialization of large corneal epithelial defects Following the findings from the results, EyeGate intends to further develop the gel with a double-masked

Prior to this synthetic route, bryostastin-1 had to be isolated from tons of natural sources to obtain grams of the drug. Bryostatin-1 is a complex marine natural product

It will leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

The approval is based on a large clinical database, comprising data from over 1,300 patients with cUTI across phase 3 studies, including several patients with infections due to

It is the first adalimumab biosimilar candidate recommended for EMA approval. It has been recommended to treat certain inflammatory ailments in adults like moderate-to-severe rheumatoid arthritis, severe ankylosing spondylitis